Get the Stockscreener App
1.315
3.13%
0.035
Heron Therapeutics Inc stock is traded at $1.315, with a volume of 167.66K.
It is up +3.13% in the last 24 hours and up +4.76% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$1.28
Open:
$1.29
24h Volume:
167.66K
Relative Volume:
0.10
Market Cap:
$241.06M
Revenue:
$137.74M
Net Income/Loss:
$-27.97M
P/E Ratio:
-8.2188
EPS:
-0.16
Net Cash Flow:
$-9.61M
1W Performance:
-1.49%
1M Performance:
+4.76%
6M Performance:
-30.89%
1Y Performance:
-28.26%
1-Day Range:
$1.285
$1.33
1-Week Range:
$1.275
$1.385
52-Week Range:
$1.04
$2.68
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.315 | 234.64M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.02 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.69 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.75 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.67 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Initiated | H.C. Wainwright | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Heron Therapeutics Inc. stock prediction for this weekQuarterly Performance Summary & Technical Buy Zone Confirmation - newser.com
Cyndeo Wealth Partners LLC Takes Position in Heron Therapeutics, Inc. $HRTX - MarketBeat
Is Heron Therapeutics Inc AXD2 a good long term investment - earlytimes.in
Heron Therapeutics (NASDAQ:HRTX) Upgraded at Zacks Research - Defense World
Heron Therapeutics (NASDAQ:HRTX) Stock Rating Upgraded by Zacks Research - MarketBeat
Chart based analysis of Heron Therapeutics Inc. trendsBear Alert & Momentum Based Trading Signals - newser.com
How Heron Therapeutics Inc. (AXD2) stock reacts to stronger dollarMarket Sentiment Report & Real-Time Buy Signal Notifications - newser.com
Heron Therapeutics (NASDAQ:HRTX) Earns "Sell (E+)" Rating from Weiss Ratings - MarketBeat
Why Heron Therapeutics Inc. stock could benefit from AI revolutionMarket Sentiment Review & Verified Momentum Watchlists - newser.com
Why Heron Therapeutics Inc. is moving today2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
Heron Therapeutics Inc. stock retracement – recovery analysisTrade Exit Summary & Entry Point Confirmation Alerts - newser.com
Is Heron Therapeutics Inc. stock positioned well for digital economyShort Setup & Smart Money Movement Alerts - newser.com
Why Heron Therapeutics Inc. stock remains on buy lists2025 AllTime Highs & Verified Short-Term Plans - newser.com
What data driven models say about Heron Therapeutics Inc.’s future - newser.com
Why Heron Therapeutics Inc. (AXD2) stock could be top winnerChart Signals & Smart Money Movement Tracker - newser.com
Published on: 2025-10-01 09:34:43 - newser.com
Chart overlay techniques for tracking Heron Therapeutics Inc.Trade Analysis Summary & Reliable Price Breakout Alerts - newser.com
Why Heron Therapeutics Inc. (AXD2) stock signals breakout potentialJuly 2025 Earnings & Consistent Growth Equity Picks - newser.com
What analysts say about Heron Therapeutics Inc AXD2 stockFundamental Strength Indicators & Free Hedging Tactics for Volatile Markets - Early Times
Is Heron Therapeutics Inc a good long term investmentSector Rotation Strategies & Free Dynamic Capital Growth - Early Times
Heron Therapeutics Strengthens Financial Position with Refinancing - MSN
Heron Therapeutics, Inc. $HRTX Shares Acquired by Congress Park Capital LLC - MarketBeat
Aug Spikes: Is Heron Therapeutics Incs growth already priced inJuly 2025 Snapshot & Safe Swing Trade Setups - خودرو بانک
Momentum Shift: Can Heron Therapeutics Inc sustain its profitabilityWeekly Profit Report & Safe Entry Zone Tips - خودرو بانک
Heron Therapeutics, Inc. (HRTX) Stock Analysis: Exploring a 292.56% Potential Upside in Biotechnology - DirectorsTalk Interviews
Heron Therapeutics Adopts Tax Benefit Preservation Plan - MSN
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Heron Therapeutics Inc Stock (HRTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):